Scores by kind of claim
Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.
-
Factual claims
Statements about the present or the past, checked against the record: did they hold up?
81 76 87 -
Predictions
Statements about events outside the person's control, checked once they fell due: did they come true?
Insufficient record: 2 predictions resolved, 5 needed for a score.
-
Promises
Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?
65 45 83
All types combined: 80 (likely 75 to 85, high confidence), from 84 claims: 78 factual claims, 6 promises. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.
Demis Hassabis's claims
37 claims
“Already, through our early collaborations, we’ve seen promising signals from researchers using AlphaFold in their own work.”
Demis Hassabis, DeepMind CEO, on DeepMind blog 22 July 2021 Putting the power of AlphaFold into the world's hands (Google DeepMind)
Through early collaborations DeepMind has seen promising signals from researchers using AlphaFold, including DNDi and the University of Portsmouth's Centre for Enzyme Innovation.
Resolved true The record shows it happened or was so.
Said for an organisation they lead or work for; it counts on both records.
What would count as true or false
True: as of 22 July 2021, DeepMind publications or partner statements document early collaborations in which external researchers, including DNDi (Drugs for Neglected Diseases initiative) and the University of Portsmouth's Centre for Enzyme Innovation, used AlphaFold and reported useful or promising results. Mostly true: early collaborations with promising results are documented, but one of the two named partners is not clearly documented as such. Mixed: collaborations existed, but there is little evidence of promising results, or neither named partner is confirmed. Mostly false: the only evidence is DeepMind's own general statement, with no documented collaborators or outcomes. False: the evidence shows no such early collaborations, or that the named partners did not use AlphaFold.
Evidence
- DeepMind and EMBL release the most complete database of predicted 3D structures of human proteins EMBL-EBI · 22 July 2021
“AlphaFold is already being used by partners such as the Drugs for Neglected Diseases Initiative (DNDi), which has advanced their research into life-saving cures for diseases that disproportionately affect the poorer parts of the world, and the Centre for Enzyme Innovation (CEI) is using AlphaFold to help engineer faster enzymes”
- Enzyme researchers partner with pioneering AI company DeepMind University of Portsmouth · 22 July 2021
“Being given access to AlphaFold has transformed our research strategy, and we are excited to be partnering with DeepMind to explore other ways in which AI can accelerate our scientific discoveries”
- Enzyme researchers partner with pioneering AI company DeepMind University of Portsmouth · 22 July 2021
“AlphaFold provides us with an exciting new library of templates to engineer faster, more stable and cheaper enzymes for plastic recycling.”
- Nobel prize for chemistry awarded to Demis Hassabis and John Jumper for AlphaFold, an AI model used by DNDi for neglected diseases Drugs for Neglected Diseases initiative (DNDi) · 10 October 2024
“As early adopters of AlphaFold, DeepMind’s artificial intelligence (AI) protein structure prediction model developed by Hassabis and Jumper, DNDi teams and partners have used the game-changing technology to find innovative ways to accelerate drug discovery”
Reasoning
EMBL-EBI's announcement of 22 July 2021 (E1) says DNDi was already using AlphaFold to advance its research into cures for neglected diseases, and that the Centre for Enzyme Innovation was using it to help engineer faster enzymes. The University of Portsmouth's own statements on the same date (E2, E3) say that access to AlphaFold had transformed the Centre's research strategy and gave it new templates for engineering better plastic-recycling enzymes. DNDi's 2024 statement (E4) calls DNDi an early adopter of AlphaFold, which confirms the collaboration. Both named partners are therefore documented as of the judging date as early collaborators reporting promising results.
Cite this claim
Demis Hassabis, “Through early collaborations DeepMind has seen promising signals from researchers using AlphaFold, including DNDi and the University of Portsmouth's Centre for Enzyme Innovation.” (said 22 July 2021). Verdict: resolved true. Reliability API, claim c_ee191761af7c, method 0.1.0+c876030c. https://epistacklabs.com/claims/c_ee191761af7c
Claims without a verdict
Is a verdict here wrong, or do you speak for Demis Hassabis? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.